EE03973B1 - Faktori Xa inhibiitorid - Google Patents

Faktori Xa inhibiitorid

Info

Publication number
EE03973B1
EE03973B1 EE9600146A EE9600146A EE03973B1 EE 03973 B1 EE03973 B1 EE 03973B1 EE 9600146 A EE9600146 A EE 9600146A EE 9600146 A EE9600146 A EE 9600146A EE 03973 B1 EE03973 B1 EE 03973B1
Authority
EE
Estonia
Prior art keywords
activity
factor
compound
amino acids
provides
Prior art date
Application number
EE9600146A
Other languages
English (en)
Estonian (et)
Other versions
EE9600146A (et
Inventor
Al-Obeidi Fahad
Lebl Michal
A. Ostrem James
Safar Pavel
Stierandova Alena
Strop Peter
Walser Armin
Original Assignee
Selectide Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selectide Corporation filed Critical Selectide Corporation
Publication of EE9600146A publication Critical patent/EE9600146A/xx
Publication of EE03973B1 publication Critical patent/EE03973B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
EE9600146A 1994-04-26 1995-04-25 Faktori Xa inhibiitorid EE03973B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23305494A 1994-04-26 1994-04-26
PCT/US1995/005268 WO1995029189A1 (en) 1994-04-26 1995-04-25 FACTOR Xa INHIBITORS

Publications (2)

Publication Number Publication Date
EE9600146A EE9600146A (et) 1997-04-15
EE03973B1 true EE03973B1 (et) 2003-02-17

Family

ID=22875692

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9600146A EE03973B1 (et) 1994-04-26 1995-04-25 Faktori Xa inhibiitorid

Country Status (27)

Country Link
EP (2) EP0758341B1 (fi)
JP (1) JP3655632B2 (fi)
KR (1) KR100380124B1 (fi)
CN (1) CN1181091C (fi)
AT (1) ATE262536T1 (fi)
AU (1) AU707653B2 (fi)
CA (1) CA2186497C (fi)
CZ (1) CZ296439B6 (fi)
DE (1) DE69532754T2 (fi)
DK (1) DK0758341T3 (fi)
EE (1) EE03973B1 (fi)
ES (1) ES2214500T3 (fi)
FI (1) FI120494B (fi)
HU (1) HUT76346A (fi)
IL (1) IL113505A (fi)
LT (1) LT4218B (fi)
LV (1) LV11740B (fi)
NO (1) NO318759B1 (fi)
NZ (1) NZ284977A (fi)
PL (1) PL188132B1 (fi)
PT (1) PT758341E (fi)
RU (1) RU2152954C1 (fi)
SI (1) SI9520044B (fi)
SK (1) SK286094B6 (fi)
TW (1) TW409129B (fi)
WO (1) WO1995029189A1 (fi)
ZA (1) ZA953361B (fi)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9607582A (pt) 1995-02-17 1998-07-07 Basf Ag Composto e peptídeo ou substância peptidomimética
US5747458A (en) * 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands
US6069130A (en) * 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
CN1087349C (zh) * 1995-12-20 2002-07-10 阿温蒂斯药物公司 N-乙酰基-(L)-4-氰基苯丙氨酸Ac-(L)-Phe(4-CN)-OH与N-乙酰基-(L)-对脒基苯丙氨酸-环己基甘氨酸-β-(3-N-甲基吡啶鎓)-丙氨酸AC-(L)-PAPh-chg-PaIMe(3)-NH2的新颖的制备方法
US5766932A (en) * 1995-12-20 1998-06-16 Hoechst Marion Roussel, Inc. Process for preparing N-acetyl(L)-4-cyanophenylalanine from a mixture of the corresponding D,L ethyl esters using subtilisin
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
US6063794A (en) 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
US6133256A (en) * 1997-04-14 2000-10-17 Cor Therapeutics Inc Selective factor Xa inhibitors
JP2002514214A (ja) 1997-04-14 2002-05-14 シーオーアール セラピューティクス インコーポレイテッド 選択的Xa因子阻害剤
EP0977772A1 (en) 1997-04-14 2000-02-09 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
US7109326B2 (en) 1997-04-15 2006-09-19 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
GB9727123D0 (en) * 1997-12-22 1998-02-25 Int Centre Genetic Eng & Bio Synthesis of diamines
CZ298827B6 (cs) 1997-12-24 2008-02-20 Sanofi - Aventis Deutschland GmbH Deriváty indolu jako inhibitory faktoru Xa, zpusob jejich prípravy a farmaceutická kompozice, kteráje obsahuje
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
EP1016663A1 (en) * 1999-01-02 2000-07-05 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
BR9916732A (pt) * 1999-01-02 2001-09-25 Aventis Pharma Gmbh Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa)
KR20010089753A (ko) * 1999-01-02 2001-10-08 로버트 흐라이탁, 미쉘 베스트 아릴알카노일 유도체, 이의 제조방법, 이의 용도 및 이를함유하는 약제학적 조성물
EP1022268A1 (en) * 1999-01-02 2000-07-26 Aventis Pharma Deutschland GmbH Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
CN1172905C (zh) 1999-12-14 2004-10-27 昭和电工株式会社 生产氰基苄胺盐的方法
JP5088598B2 (ja) * 1999-12-14 2012-12-05 昭和電工株式会社 シアノベンジルアミン類の塩の製造方法
RU2250212C2 (ru) * 2000-01-28 2005-04-20 Авентис Фарма Дойчланд Гмбх Способ получения ацетиламидиниофенилаланилциклогексилглицилпиридиниоаланинамидов
EP1127884A1 (en) * 2000-02-26 2001-08-29 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them
DE10029015A1 (de) * 2000-06-15 2001-12-20 Curacyte Ag Hemmstoffe für den Gerinnungsfaktor Xa
DE60126143T2 (de) 2000-12-06 2007-11-15 Sanofi-Aventis Deutschland Gmbh Guanidin- und amidin-verbindungen, und ihre verwendung als faktor xa-inhibitoren
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
DE50310038D1 (de) 2002-03-11 2008-08-07 Curacyte Ag Hemmstoffe der urokinase, ihre herstellung und verwendung
PT1569912E (pt) 2002-12-03 2015-09-15 Pharmacyclics Llc Derivados 2-(2-hidroxibifenil-3-il)-1h-benzoimidazole-5- carboxamidina como inibidores do fator viia
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
EP1479680A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Azaindole derivatives as Factor Xa inhibitors
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
DE10342108A1 (de) 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
US7446210B2 (en) 2004-10-26 2008-11-04 Janssen Pharmaceutica N.V. Factor Xa compounds
EP1724269A1 (en) 2005-05-20 2006-11-22 Sanofi-Aventis Deutschland GmbH Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors
DE102005044319A1 (de) 2005-09-16 2007-03-22 Curacyte Chemistry Gmbh 2-(Aminomethyl)-5-Chlor-Benzylamid-Derivate und ihre Verwendung als Hemmstoffe des Gerinnungsfaktors Xa
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
EP1918718A1 (de) * 2006-10-31 2008-05-07 Roche Diagnostics GmbH Verfahren und Vorrichtungen zur elektrochemischen Bestimmung von Faktor Xa-Inhibitoren in Blutproben
EP2591783A1 (en) 2007-04-13 2013-05-15 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275153A (en) * 1978-08-03 1981-06-23 American Hospital Supply Corporation Analytical fluorogenic substrates for proteolytic enzymes
CA1161431A (en) * 1979-05-11 1984-01-31 Lars G. Svendsen Tripeptide derivatives
US4469679A (en) * 1983-02-16 1984-09-04 Smithkline Beckman Corporation Octapeptide vasopressin antagonists
HU191961B (en) * 1984-08-02 1987-04-28 Richter Gedeon Vegyeszet Process for producing 1,5 and 8 substituted peptides of angiotenzin-ii antagonistic activity
DE69321344D1 (de) * 1992-02-14 1998-11-05 Corvas Int Inc Inhibitoren der thrombose

Also Published As

Publication number Publication date
ZA953361B (en) 1996-01-12
HUT76346A (en) 1997-08-28
LT4218B (en) 1997-09-25
NZ284977A (en) 1998-09-24
PL188132B1 (pl) 2004-12-31
CZ296439B6 (cs) 2006-03-15
ES2214500T3 (es) 2004-09-16
FI964317A0 (fi) 1996-10-25
CA2186497C (en) 2008-06-17
SK136696A3 (en) 1997-05-07
EE9600146A (et) 1997-04-15
LV11740A (lv) 1997-04-20
PL317067A1 (en) 1997-03-03
EP0758341B1 (en) 2004-03-24
IL113505A0 (en) 1995-07-31
CN1181091C (zh) 2004-12-22
NO964553D0 (no) 1996-10-25
JPH10503477A (ja) 1998-03-31
DK0758341T3 (da) 2004-06-28
AU2368395A (en) 1995-11-16
CZ314096A3 (en) 1997-05-14
WO1995029189A1 (en) 1995-11-02
EP1384725A3 (en) 2007-02-21
DE69532754D1 (de) 2004-04-29
DE69532754T2 (de) 2005-03-10
FI964317A (fi) 1996-10-25
IL113505A (en) 1999-12-31
JP3655632B2 (ja) 2005-06-02
CA2186497A1 (en) 1995-11-02
EP1384725A2 (en) 2004-01-28
AU707653B2 (en) 1999-07-15
SI9520044B (sl) 2004-08-31
ATE262536T1 (de) 2004-04-15
KR100380124B1 (ko) 2003-08-02
FI120494B (fi) 2009-11-13
EP0758341A1 (en) 1997-02-19
SI9520044A (en) 1997-10-31
HU9602954D0 (en) 1996-12-30
NO318759B1 (no) 2005-05-02
NO964553L (no) 1996-12-27
CN1147261A (zh) 1997-04-09
RU2152954C1 (ru) 2000-07-20
LT96151A (en) 1997-05-26
SK286094B6 (sk) 2008-03-05
LV11740B (en) 1997-12-20
PT758341E (pt) 2004-08-31
TW409129B (en) 2000-10-21

Similar Documents

Publication Publication Date Title
EE9600146A (et) Faktori Xa inhibiitorid
DE69729583D1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
NZ500620A (en) Synthetic peptides which inhibit serine proteases, specifically thrombin, factor VIIa tissue factor and factor Xa
CO5261542A1 (es) Nuevos derivados tripeptidos como inhibidores de la hepatitis c, comprendiendo sus racematos, diasteroisomeros y procedimiento de preparacion
ATE346928T1 (de) Aus nematoden extrahierte serinprotease- inhibitoren und die koagulation hemmende proteine
DK0816376T3 (da) Thrombininhibitorer som antikoagulante midler
SE9602263D0 (sv) New amino acid derivatives
FI942625A0 (fi) Peptidisiä fosfinyylioksimetyyliketoneja interleukiini-1beta-muuttuvan entsyymin inhibiittoreina
ATE181925T1 (de) Hemmstoffe für kathepsin-g und elastase zur verhütung von bindegewebsabbau
ATE153670T1 (de) Peptidboronsäurederivate mit protease inhibierenden aktivität
ES2168816T3 (es) Cemento de inyeccion que contiene inhibidores de la corrosion.
ATE289319T1 (de) Dipeptidische hemmstoffe für den gerinnungsfaktor xa
MX9605037A (es) Inhibidores de factor xa.
DE59812724D1 (de) Serin-proteinase-inhibitoren
DE69615185D1 (de) Faktor ix bindende peptide abgeleitet von faktor vii und ihre verwendung als inhibitoren der blutgerinnung
BR0315219A (pt) Método para a purificação de um lantibiótico
ATE94168T1 (de) Peptide.
DE60220185D1 (de) Screening-verfahren für substanzen zur behandlung von diabetes
RU94037136A (ru) Имидазолсодержащие ингибиторы катепсин-g-индуцированной агрегации тромбоцитов
TH38361A (th) สารยับยั้งเซรีนโปรทีเอส
HUP9601528A2 (hu) Véralvadásgátló hatású peptidszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények
TH20752EX (th) อนุพันธ์เพพไทด์ชนิดใหม่

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110425